Major Drugmaker Sees Huge Sales Growth From Diabetes and Weight-Loss Medications
A major pharmaceutical company recently shared its financial results for the second quarter, showing growth that went far beyond what financial experts predicted. Because of the massive popularity of its main diabetes and weight-loss treatments, the company has raised its financial targets for the rest of the year.
The drugmaker now projects its upcoming yearly revenue to reach between $85 billion and $87 billion. This is an increase from its earlier estimate of $82 billion to $85 billion. The company also adjusted its expected profit for the full year to be between $35.50 and $36.50 per share, compared to the previous estimate of $35.50 to $37 per share. While the company raised its core profit expectations by $2.78 per share, this was balanced out by $3.03 per share in costs related to business deals made during the quarter.
Strong Sales and Big Business Deals
With a large amount of money coming in from its popular health treatments, the company is actively buying other businesses. Recently, the drugmaker agreed to purchase a company that develops psychedelic medicines. Earlier in the year, it also announced plans to acquire three companies that make vaccines.
Following the release of these financial results, the company's stock price jumped by more than 5% before the stock market opened for regular trading. The company's chief executive officer shared that the business is starting the year in an incredibly strong position, noting that it is hard to recall a time when the company was doing better.
Here is how the actual financial results for the second quarter compared to what financial analysts expected:
- Adjusted earnings per share: $8.38 actual compared to the $6.01 that was expected.
- Total revenue: $22.97 billion actual compared to the $20.73 billion that was expected.
Leading the Market in Weight-Loss and Diabetes Care
The company continues to hold a dominant position in the rapidly growing market for a popular class of treatments known as GLP-1 drugs. During the second quarter, the company held a 60.9% share of the United States market for obesity and diabetes treatments. Its main competitor held a 38.8% share of the market during the same period.
Even though the prices of these medications have decreased in the United States, steady demand has kept sales very strong. Here is how the company's individual products performed during the quarter:
- Mounjaro: Global sales for this diabetes drug rose by 91% to reach $9.94 billion, with $4.8 billion of that total coming from the United States. This beat the expected global sales of $8.99 billion and U.S. sales of $4.44 billion. International sales for this drug were especially strong, growing by 172%. The company noted that many patients in middle-income countries like Brazil, China, and India are paying for this drug out of their own pockets, creating steady and lasting demand.
- Zepbound: This weight-loss drug, which first came to the market about three years ago, brought in $4.93 billion in U.S. revenue during the quarter. This is a 44% increase compared to the same period in the previous year. Although the price of the drug went down partly due to cash discounts, overall demand rose. Analysts had expected U.S. sales to be around $4.69 billion.
- Foundayo: This newly released weight-loss pill, which received official approval earlier this year, brought in $98 million in sales. This was slightly lower than the estimated $103 million. However, the company's leader expressed satisfaction with this start, noting that consumer awareness and actual prescriptions both doubled in a single month. Currently, about one-quarter of all new patients starting on oral weight-loss medications are choosing this new pill.
A Look at Regional Sales and Future Trends
In the United States, the company's revenue grew by 33% to reach $14.4 billion. The total volume of products sold in the U.S. rose by 37%, mostly driven by higher demand for Mounjaro and Zepbound, though this growth was slightly affected by lower prices. Outside of the United States, revenue increased by 80% to reach $8.6 billion. This international growth was driven by a 113% increase in the volume of products sold, even though average prices fell by 36%. The lower prices abroad were mainly due to Mounjaro being added to a state-run health insurance program in China.
Overall, the pharmaceutical company reported a net income of $7.10 billion (or $7.94 per share) for the quarter, which includes the costs from business acquisitions. This is up from a net income of $5.66 billion (or $6.29 per share) during the same period in the previous year. If one-time adjustments are excluded, the company earned $8.38 per share.
Looking ahead, leadership expects that lower prices will help more patients access these treatments. The company estimates that the total number of people worldwide using GLP-1 medications will grow from roughly 20 million at the end of the previous year to 30 million in the near future. Additionally, both this company and its main competitor are expected to benefit from new government healthcare coverage for obesity drugs, which recently began allowing eligible older adults to access these brand-name treatments for a monthly co-pay of $50.
The company's leadership mentioned that the rollout of this new coverage is off to a strong start. They expressed confidence that this policy change will make a major difference in healthcare costs and help older adults live longer, healthier lives.